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Abstract 
The mechanisms by which stressful life events increase the risk of relapse in recovering cocaine addicts 
are not well understood. We previously reported that stress, via elevated corticosterone, potentiates 
cocaine-primed reinstatement of cocaine seeking following self-administration in rats and that this 
potentiation appears to involve corticosterone-induced blockade of dopamine clearance via the organic 
cation transporter 3 (OCT3). In the present study, we use a conditioned place preference/reinstatement 
paradigm in mice to directly test the hypothesis that corticosterone potentiates cocaine-primed 
reinstatement by blockade of OCT3. Consistent with our findings following self-administration in rats, 
pretreatment of male C57/BL6 mice with corticosterone (using a dose that reproduced stress-level 
plasma concentrations) potentiated cocaine-primed reinstatement of extinguished cocaine-induced 
conditioned place preference. Corticosterone failed to re-establish extinguished preference alone but 
produced a leftward shift in the dose–response curve for cocaine-primed reinstatement. A similar 
potentiating effect was observed upon pretreatment of mice with the non-glucocorticoid OCT3 blocker, 
normetanephrine. To determine the role of OCT3 blockade in these effects, we examined the abilities of 
corticosterone and normetanephrine to potentiate cocaine-primed reinstatement in OCT3-deficient and 
wild-type mice. Conditioned place preference, extinction and reinstatement of extinguished preference 
in response to low-dose cocaine administration did not differ between genotypes. However, 
corticosterone and normetanephrine failed to potentiate cocaine-primed reinstatement in OCT3-deficient 
mice. Together, these data provide the first direct evidence that the interaction of corticosterone with 
OCT3 mediates corticosterone effects on drug-seeking behavior and establish OCT3 function as an 
important determinant of susceptibility to cocaine use. 
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INTRODUCTION 
Glucocorticoids exert profound effects on behavior and are critical mediators of adaptive stress 
responses. Although glucocorticoid-mediated stress responses are often attributed to transcriptional 
regulation resulting from activation of the cytosolic glucocorticoid receptor (GR), a growing body of 
evidence suggests that many glucocorticoid effects, particularly those that involve acute regulation of 
behavior, are mediated by non-canonical, GR-independent mechanisms. One such mechanism appears to 
involve impairment of monoamine clearance via a direct inhibition of the low-affinity, high-capacity 
monoamine transporter, organic cation transporter 3 (OCT3). 
It has long been known that corticosteroids impair monoamine clearance mediated by what historically 
has been termed uptake2, a high-capacity transport system originally characterized in peripheral tissues 
(Iversen and Salt, 1970). More recently, uptake2-mediated monoamine clearance has been attributed to a 
group of transporters that includes the organic cation transporter (OCT) family (OCTs 1, 2, and 3) and 
the plasma membrane monoamine transporter (PMAT) (Gründemann et al, 1998a; Shang et al, 
2003; Gorboulev et al, 2005; Schomig et al, 1998; Duan and Wang, 2010). All of these transporters have 
been reported to be expressed in the brain, although levels of OCT1 expression are likely very low 
(Schmitt et al, 2003; Engel et al, 2004; Vialou et al, 2004; Amphoux et al, 2006; Baganz et al, 
2008; Gasser et al, 2009). Although each of these transporters is sensitive to inhibition by corticosterone, 
there is significant variation in sensitivity. Among these transporters, PMAT is the least sensitive to 
corticosterone (Ki=450 μm), followed by OCT1 (IC50=150 μm), OCT2 (IC50=5 μm), and OCT3 
(IC50=0.04–0.2 μm) (Gründemann et al, 1998b; Shang et al, 2003; Gorboulev et al, 2005; Schomig et al, 
1998; Duan and Wang, 2010). Thus it appears that OCT3 is the only uptake2 transporter sensitive to 
inhibition by corticosterone at concentrations observed during stress. Corticosterone-induced inhibition 
of OCT3-mediated transport is GR-independent, non-genomic, and likely involves direct binding to 
OCT3 (Gründemann et al, 1999; Horvath et al, 2003; Gorboulev et al, 2005). Moreover, it appears to 
elevate monoamine levels in vivo (Gasser et al., 2006; Baganz et al., 2010; Graf et al, 2013), posing it as 
a potential GR-independent mechanism through which glucocorticoids regulate behavior. However, to 
date, there is no direct evidence that glucocorticoids exert actions on behavior via inhibition of OCT3. 
Glucocorticoid-mediated stress-adaptive responses include altered processing of motivational and 
rewarding stimuli. A consequence of such alterations appears to be a heightened susceptibility to drug-
seeking behavior. We recently established a rat self-administration/reinstatement model in which acute 
stress potentiates the reinstatement of cocaine seeking in response to an otherwise subthreshold priming 
dose of cocaine but does not by itself directly evoke cocaine seeking (Graf et al, 2013; McReynolds et 
al., 2016). This stage-setting effect of stress appears to be mediated by glucocorticoids, in that the ability 
of footshock to potentiate reinstatement in response to a subthreshold low dose of cocaine is eliminated 
by adrenalectomy, and mimicked in the absence of stress by administration of corticosterone at a dose 
that results in plasma levels comparable to those observed during stress. The effect also appears to be 
mediated by a GR-independent mechanism, as it is insensitive to pretreatment with the GR antagonist 
RU38486 (Graf et al, 2013). A role for inhibition of OCT3 in these actions of corticosterone is 
suggested by the fact that corticosterone potentiates low-dose cocaine-induced increases in nucleus 
accumbens (NAc) dopamine, that corticosterone treatment decreases dopamine clearance in the NAc via 
a DAT-independent mechanism, and that corticosterone-induced potentiation of reinstatement is 
mimicked by treatment with normetanephrine, a non-glucocorticoid blocker of OCT3-mediated 
transport (Graf et al, 2013). 
Although the above findings suggest that the effects of corticosterone on cocaine seeking may be 
attributable to its ability to inhibit OCT3-mediated dopamine clearance, definitive evidence that these 
effects are mediated by inhibition of OCT3 is lacking. To address this, we sought to examine the effects 
of corticosterone on cocaine-seeking behavior in mutant mice deficient in OCT3 function (Zwart et al, 
2001; Vialou et al, 2008; Cui et al, 2009). Here we establish a mouse model wherein corticosterone 
potentiates the reinstatement of extinguished cocaine-induced conditioned place preference (CPP) 
resulting from priming injections of cocaine. Using this model, we report that the ability of stress-level 
corticosterone or normetanephrine to potentiate cocaine-induced reinstatement following CPP requires 
functional expression of OCT3, thereby providing the first direct evidence that acute behavioral effects 
of corticosterone can result from its interaction with OCT3. 
MATERIALS AND METHODS 
Subjects 
Male C57BL/6 mice were purchased from Harlan Laboratories and used for Experiment #1. Male 
OCT3-deficient and wild-type control mice (Zwart et al, 2001; see Supplementary Materials and 
Methods) were used for Experiment #2. Mice were housed individually in a humidity- and temperature-
controlled, AAALAC-accredited animal facility under a 12 h/12 h light/dark cycle (lights on at 0700 
hours) with food and water available ad libitum, except when in the experimental chambers, and were 
tested starting at an age of 8–10 weeks. All procedures were carried out in compliance with the NIH 
guidelines and the Guide for Care and Use of Laboratory Animals. 
CPP, Extinction, and Reinstatement 
CPP was conducted as previously described (Mantsch et al, 2010; Vranjkovic et al, 2012; 
see Supplementary Materials and Methods). Briefly, following determination of initial preference, 
compartments in a three-compartment apparatus were paired with cocaine (15 mg/kg, ip) or saline 
during alternating 30-min conditioning sessions over an 8-day period using a biased approach. CPP was 
defined according to the time spent in the cocaine-paired compartment relative to preconditioning. Mice 
that displayed CPP underwent daily extinction training during the 30-min sessions until the extinction 
criterion was met, at which point reinstatement testing began the next day (see Supplementary Materials 
and Methods). Reinstatement testing conditions were identical to extinction except that the sessions 
were immediately preceded by cocaine priming injections that followed pretreatment with 
corticosterone, normetanephrine, or saline. Most mice underwent repeated reinstatement testing, in 
which case reinstatement sessions were separated by additional extinction training with a requirement 
that the extinction criterion was met prior to the next reinstatement test. 
Experiment 1: Effects of Corticosterone and the Non-Glucocorticoid OCT3 Blocker, 
Normetanephrine, on Cocaine-Primed Reinstatement Following CPP in C57 BL/6 mice 
We initially tested C57BL/6 mice for the effects of pretreatment with corticosterone; the non-
glucocorticoid OCT3 inhibitor, normetanephrine; or vehicle on cocaine-primed reinstatement. Soluble 
HBC-complexed corticosterone (2 mg/kg corticosterone; Sigma-Aldrich) and normetanephrine 
(2.5 mg/kg; Sigma-Aldrich) were dissolved in saline. Doses were selected based on our findings that 
they potentiated cocaine-primed reinstatement following self-administration in rats (Graf et al, 2013). 
Following CPP and extinction, mice were tested for reinstatement in response to a range of cocaine 
doses (0, 0.93, 1.875, 3.75, 7.5, 15 mg/kg, ip), 40 min after corticosterone, normetanephrine, or saline 
pretreatment. Each mouse was tested multiple times and received no more than six combinations of 
saline, normetanephrine, or corticosterone pretreatment/cocaine doses in randomized sequence (average 
of four tests). Pretreatment effects were assessed using two-way ANOVAs with cocaine dose and 
pretreatment as between-subject measures. Reinstatement was defined as the change in the time spent in 
the cocaine-paired compartment relative to the prior extinction session. 
To determine plasma corticosterone levels resulting from HBC-corticosterone administration, mice were 
decapitated 40 min after ip corticosterone or saline administration and trunk blood was collected and 
plasma isolated for measurement of corticosterone using a commercial RIA Kit (MP Biomedicals). To 
allow comparison with stressor-induced corticosterone levels, a separate group of mice underwent a 6-
min forced swim in 22 °C water (Mantsch et al, 2010) prior to decapitation and trunk blood collection, 
40 min later. Plasma corticosterone levels following ip vehicle or corticosterone administration were 
also measured in wild-type and OCT3-deficient mice (see Experiment 2). 
Experiment 2: Contribution of OCT3 to Corticosterone- and Normetanephrine-
Potentiated Reinstatement 
To examine the contribution of OCT3 to corticosterone- and normetanephrine-potentiated reinstatement, 
separate groups of OCT3-deficient and wild-type mice underwent CPP followed by extinction and were 
tested for reinstatement in response to ip saline or low-dose (0.93 mg/kg) cocaine after pretreatment with 
corticosterone, normetanephrine, or vehicle. The 0.93 mg/kg cocaine dose was selected because, in 
C57BL/6 mice, (1) it was subthreshold in terms of reinstatement and (2) robust corticosterone- and 
normetanephrine-induced potentiation was observed at this cocaine dose. Each mouse was tested for 
reinstatement at least twice (once with corticosterone, normetanephrine, or vehicle administered prior to 
injection with 0.93 mg/kg cocaine and once for the same treatment prior to a saline injection) and as 
many as four times. Each reinstatement test was separated by additional extinction sessions with the 
requirement that extinction-level preference was re-established prior to retesting. Separate two-way 
pretreatment × cocaine treatment ANOVAs were conducted in each genotype with planned comparisons 
for pretreatment effects at the 0. 93 mg/kg dose. 
To determine whether OCT3 deficiency alone promoted low-dose cocaine-induced reinstatement, we 
compared pooled reinstatement data from all vehicle-pretreated wild-type mice with pooled data from 
all vehicle-pretreated OCT-deficient mice and conducted a two-way (genotype × cocaine/saline 
treatment) ANOVA. Additionally, to more closely examine differences in corticosterone and 
normetanephrine effects across genotypes, three-way genotype × pretreatment × cocaine treatment 
ANOVAs were also conducted. 
RESULTS 
Experiment #1: Effects of Corticosterone and the Non-Glucocorticoid OCT3 Inhibitor, 
Normetanephrine, on Cocaine-Primed Reinstatement of Extinguished CPP in C57BL/6 
Mice 
Overall, C57BL/6 mice displayed robust CPP and this preference was attenuated as a result of extinction 
(Figure 1a). One-way ANOVA showed a significant overall effect of test condition (preconditioning, 
postconditioning, last extinction session prior to reinstatement testing) on preference for the cocaine 
compartment (one-way ANOVA; F2,118=187.72; P<0.001). Post-hoc testing revealed that mice spent 
more time in the cocaine compartment after conditioning (P<0.05, postconditioning vs preconditioning) 
and that time spent in the cocaine compartment was reduced as a result of extinction training (P<0.05, 
last extinction vspostconditioning). There were no differences in CPP or extinction between groups of 
mice that subsequently received vehicle, corticosterone, or normetanephrine pretreatments 
(Supplementary Tables S1 and S2). A one-way ANOVA showed that cocaine dose-dependently 
reinstated extinguished CPP (F5,89=7.551; P<0.001; Figure 1b) with significant reinstatement observed 
at the 3.75, 7.5, and 15.0 mg/kg cocaine-priming doses (P<0.05 vs 0 mg/kg; Bonferroni-corrected t-
tests). No significant differences in the total time spent in the cocaine and saline compartments 
combined were observed during reinstatement testing. To examine the effects of corticosterone or 
normetanephrine pretreatment on reinstatement, separate cohorts of C57BL/6 mice were tested for 
cocaine-primed reinstatement following pretreatment with 2.0 mg/kg corticosterone, 2.5 mg/kg 
normetanephrine, or vehicle. Separate analyses were conducted to assess the effects of corticosterone 
(two-way corticosterone treatment × cocaine dose ANOVA) and normetanephrine (two-way 
normetanephrine treatment × cocaine dose ANOVA). 
Figure 1 
 
Cocaine-induced conditioned place preference (CPP), extinction, and cocaine-primed reinstatement in C57BL/6 mice. Mice 
underwent CPP at a conditioning dose of 15 mg/kg, ip prior to extinction and testing for reinstatement in response to ip 
cocaine priming doses (0–15 mg/kg, ip). Data in panel (a) represent time spent in the cocaine-paired compartment (seconds; 
mean±SE) prior to (Pre-Cond) and after (Post-Cond) conditioning and on the final day of extinction (prior to reinstatement 
testing). Data from all mice used for reinstatement testing were combined for analyses (n=66). Mice showed significant 
cocaine-induced CPP (*P<0.05 Pre- vs Post-Cond) and preference was diminished as a result of extinction training (#P<0.05 
Extinction vs Post-Cond). Data in panel (b) represent a dose–response curve for cocaine-primed reinstatement of 
extinguished preference (change in time spent in the cocaine-paired compartment relative to the prior extinction session; 
seconds, mean±SE). Cocaine dose-dependently reinstated preference for the cocaine compartment (*P<0.05 vs 0 mg/kg 
dose; n=15–26 per cocaine dose). 
 
Effects of Corticosterone on Cocaine-Primed Reinstatement 
A two-way ANOVA revealed a significant main effect of cocaine dose (F5,201=6.255; P<0.001; Figure 
2a) but not of corticosterone pretreatment on reinstatement and a significant corticosterone pretreatment 
× cocaine dose interaction (F5,201=3.537; P<0.01). Corticosterone did not induce reinstatement on its 
own but produced a leftward shift in the dose–response curve for cocaine-primed reinstatement. In 
vehicle-pretreated mice, cocaine dose-dependently reinstated cocaine seeking with significant increases 
relative to saline observed at the 3.75, 7.5, and 15 mg/kg cocaine-priming doses (P<0.05). 
Corticosterone-pretreated mice were more sensitive to cocaine-induced reinstatement and displayed 
significant reinstatement in response to 0.93 and 1.88 mg/kg cocaine, in addition to the 3.75 mg/kg 
cocaine dose. Moreover, post-hoc testing showed that, while there were no differences between 
corticosterone- and vehicle-pretreated mice at the 0 mg/kg cocaine dose, corticosterone-pretreated mice 
displayed significant increases in reinstatement relative to vehicle-pretreated mice that received either 
0.93 or 1.88 mg/kg cocaine (P<0.05; Bonferroni-corrected t-tests). At higher cocaine doses, the 
magnitude of reinstatement declined in corticosterone-pretreated mice, resulting in a descending limb in 
the reinstatement dose–response curve. The times spent in the cocaine-paired compartment on the 
reinstatement test days and preceding extinction sessions are shown in Supplementary Table S1. 
Figure 2 
 
Cocaine-primed reinstatement following CPP is potentiated by pretreatment with corticosterone or normetanephrine. Neither 
pretreatment with corticosterone (2.0 mg/kg, ip; 40 min; (a)) nor normetanephrine (2.5 mg/kg, ip; 40 min; (b)) reinstated 
extinguished preference alone, but each potentiated cocaine-primed reinstatement as indicated by a leftward shift in the dose–
response curve for cocaine-primed reinstatement. Data represent the change in the time spent in the cocaine-paired 
compartment (sec; mean±SE) upon reinstatement testing relative to the prior extinction session. Separate cohorts of mice 
were pretreated with vehicle (n=15–26 per cocaine dose), corticosterone (Cort; n=12–20 per cocaine dose), and 
normetanephrine (Normet; n=13–18 per cocaine dose). Separate analyses were conducted comparing the effects of vehicle 
and corticosterone (a) and vehicle and normetanephrine (b) on cocaine-primed reinstatement. Cocaine dose-dependently 
increased preference (#P<0.05), and reinstatement of CPP in response to lower doses of cocaine was augmented following 
pretreatment with corticosterone or normetanephrine (*P<0.05 vs Vehicle). 
 Corticosterone administration significantly increased blood levels relative to vehicle injection 
(t17=11.50; P<0.001; two-tailed t-test; Supplementary Table S3). Although plasma corticosterone 
concentrations resulting from corticosterone administration were significantly higher than those 
resulting from forced swim (t23=5.70; P<0.001; two-tailed t-test), they were within previously reported 
stress-induced ranges (Aliczki et al, 2013; Gong et al, 2015; Malisch et al, 2007). 
Effects of Normetanephrine on Cocaine-Primed Reinstatement 
A two-way ANOVA showed a significant main effect of cocaine dose (F5,186=6.823; P<0.001) but not of 
normetanephrine pretreatment on reinstatement and a significant normetanephrine pretreatment × 
cocaine dose interaction (F5,186=2.967; P<0. 05; Figure 2b). Normetanephrine did not induce 
reinstatement on its own, but, similar to corticosterone, it shifted the dose–response curve for cocaine-
primed reinstatement to the left. In contrast to vehicle-pretreated mice, in which reinstatement was only 
observed at and above the 3.75 mg/kg cocaine priming dose, in normetanephrine-pretreated mice, 
reinstatement was observed at 0.93 and 1.88 mg/kg cocaine. Moreover, while the effects of 
normetanephrine did not differ from vehicle at the 0 mg/kg dose, normetanephrine-induced increases in 
reinstatement relative to vehicle were also observed at 0.93 and 1.88 mg/kg cocaine. With the exception 
of the 15 mg/kg cocaine dose, as the cocaine dose increased, the magnitude of reinstatement also 
declined in normetanephrine-pretreated mice, again suggestive of a descending limb in the reinstatement 
dose–response curve. The times spent in the cocaine-paired compartment on the reinstatement test days 
and preceding extinction sessions are shown in Supplementary Table S1. 
Experiment #2: Role of OCT3 in Corticosterone-Potentiated Cocaine-Primed 
Reinstatement of CPP, Extinction, and Cocaine-Primed Reinstatement in Wild-Type and 
OCT3-Deficient Mice 
No differences in cocaine-induced CPP or extinction were observed between wild-type and OCT3-
deficient mice (Figure 3a; Supplementary Table S4). A two-way conditioning session × genotype 
ANOVA showed a significant overall effect of conditioning (F1,184=203.84; P<0.0001) but no 




Cocaine-induced conditioned place preference (CPP), extinction, and cocaine-primed reinstatement in OCT3-deficient and 
wild-type mice. Cocaine-induced CPP and extinction (a) and reinstatement in response to a low dose of cocaine (0.93 mg/kg, 
ip; (b)) did not significantly differ between OCT3-deficient (n=101) and wild-type mice (n=85). Data in panel (a) represent 
time spent in the cocaine-paired compartment (seconds; mean±SE) prior to and after conditioning and on the final day of 
extinction prior to reinstatement testing in wild-type and OCT3 knockout (KO) mice. Overall, cocaine-induced CPP 
(*P<0.05 Post-Cond vs Pre-Cond) and extinction (#P<0.05 Last Ext vs Post-Cond) were observed in both genotypes and did 
not differ between wild-type and OCT3 KO mice. Data in panel (b) represent reinstatement of extinguished preference 
(change in time spent in the cocaine-paired compartment relative to the prior extinction session; seconds; mean±SE) 
following saline (0 mg/kg, ip) or low-dose cocaine (0.93 mg/kg, ip) administration in wild-type (n=26 saline; n=32 cocaine) 
and OCT3 KO mice (n=49 saline; n=57 cocaine). Overall, 0.93 mg/kg cocaine failed to reinstate preference and preference 
levels during reinstatement testing did not significantly differ between wild-type and OCT3 KO mice. 
 
As the primary objective of the experiment was to determine whether the absence of OCT3 prevents 
corticosterone- and normetanephrine-potentiated reinstatement, our primary statistical analyses 
consisted of separate two-way ANOVAs within genotypes (see below). However, to determine whether 
there were any complex interactions between pretreatment effects, cocaine-primed reinstatement, and 
OCT3 deficiency, we also conducted three-way genotype × corticosterone/normetanephrine × low-dose 
cocaine-induced reinstatement ANOVAs. These analyses failed to demonstrate significant (a) genotype 
× pretreatment interactions or (b) genotype × pretreatment × cocaine treatment interactions. We also 
tested for basal differences in reinstatement in response to 0.93 mg/kg cocaine, a dose at which both 
corticosterone and normetanephrine potentiated reinstatement in C57BL/6 mice, by comparing pooled 
data from all vehicle-pretreated wild-type and OCT3-deficient mice. A two-way cocaine treatment 
(0.93 mg/kg cocaine vs saline) × genotype ANOVA revealed no significant main effects of cocaine or 
genotype or a cocaine × genotype interaction (Figure 3b). 
Contribution of OCT3 to Corticosterone-Potentiated Cocaine-Induced Reinstatement 
Pretreatment with corticosterone potentiated cocaine-primed reinstatement in wild-type but not in 
OCT3-deficient mice (Figure 4a). A two-way cocaine treatment (0.93 mg/kg cocaine vs saline) × 
corticosterone pretreatment (2.0 mg/kg corticosterone vs vehicle) ANOVA revealed significant main 
effects of both cocaine treatment (F1,67=5.66; P<0.05) and corticosterone pretreatment 
(F1,67=4.82; P<0.05), as well as a significant cocaine treatment × corticosterone pretreatment interaction 
(F1,67=4.21; P<0.05) in wild-type mice. Post-hoc testing using Bonferroni-corrected t-tests, as well as 
planned comparisons, revealed that, compared with vehicle-pretreated mice, wild-type mice pretreated 
with corticosterone showed a significantly greater increase in time spent in the cocaine-paired compared 
compartment in response to low-dose cocaine (P<0.05). Likewise, corticosterone- but not vehicle-
pretreated wild-type mice displayed significant low-dose cocaine-induced reinstatement, as defined by a 
greater increase in time spent in the cocaine-paired compartment following 0.93 mg/kg cocaine relative 
to saline (P<0.05). In contrast, in OCT3-deficient mice, neither main effects of cocaine or corticosterone 
nor a cocaine × corticosterone interaction were observed (Figure 4b), suggesting that the effects of 
corticosterone on reinstatement were indeed mediated through its interaction with OCT3. The times 
spent in the cocaine-paired compartment on the reinstatement test days and preceding extinction 
sessions are shown in Supplementary Table S6. Plasma corticosterone levels did not differ between 




Corticosterone potentiates cocaine-primed reinstatement in wild-type but not OCT3-deficient mice. Data represent 
reinstatement of extinguished preference (change in time spent in the cocaine-paired compartment relative to the prior 
extinction session; seconds; mean±SE) following saline (0 mg/kg, ip) or low-dose cocaine (0.93 mg/kg, ip) administration in 
wild-type (a) and OCT3 KO (b) mice after pretreatment with corticosterone (Cort; 2.0 mg/kg, ip; 40 min; wild-type n=22; 
KO n=23) or vehicle (Veh; wild-type n=16; KO n=22). In wild-type mice, neither 0.093 mg/kg cocaine following vehicle 
pretreatment nor saline injection following corticosterone pretreatment reinstated preference. However, injection of 
0.093 mg/kg cocaine did reinstate preference when it was administered following corticosterone pretreatment 
(*P<0.05 vsCort/0 mg/kg cocaine and Veh/0.093 mg/kg cocaine; (a)). By contrast, no significant effects of cocaine or 
corticosterone pretreatment were observed in OCT3 KO mice (b). 
 
Contribution of OCT3 to Normetanephrine-Potentiated Cocaine-Induced Reinstatement 
Normetanephrine pretreatment also potentiated low-dose cocaine-primed reinstatement in wild-type but 
not in OCT3-deficient mice (Figure 5a). A two-way cocaine treatment (0.93 mg/kg cocaine vs saline) × 
normetanephrine pretreatment (2.5 mg/kg normetanephrine vs veh) ANOVA revealed main effects of 
both cocaine treatment (F1,97=11.15; P<0.05) and normetanephrine pretreatment (F1,97=6.68; P<0.05) in 
wild-type mice. However, despite a trend (P=0.10), a significant cocaine × normetanephrine interaction 
was not observed. Planned comparisons revealed that, compared with vehicle-pretreated mice, wild-type 
mice pretreated with normetanephrine displayed a significantly greater increase in preference in 
response to low-dose cocaine (t53=3.38; P=0.001; unpaired t-test) and that low-dose cocaine 
administration resulted in significant reinstatement in normetanephrine- but not in vehicle-pretreated 
wild-type mice (0.93 mg/kg cocaine vs saline; t41=3.35; P<0.01; unpaired t-test). By contrast, in OCT3-
deficient mice, no main effects of cocaine or normetanephrine were observed, and there was no cocaine 
× normetanephrine interaction (Figure 5b). The times spent in the cocaine-paired compartment on the 
reinstatement test days and preceding extinction sessions are shown in Supplementary Table S7. 
Figure 5 
 
Normetanephrine potentiates cocaine-primed reinstatement in wild-type but not OCT3-deficient mice. Data represent 
reinstatement of extinguished preference (change in time spent in the cocaine-paired compartment relative to the prior 
extinction session; seconds; mean±SE) following saline (0 mg/kg, ip) or low-dose cocaine (0.93 mg/kg, ip) administration in 
wild-type (a) and OCT3 KO (b) mice following pretreatment with normetanephrine (Normet; 2.5 mg/kg, ip; 40 min; wild-
type n=32; KO n=40) or vehicle (wild-type n=23; KO n=17). In wild-type mice, neither 0.093 mg/kg cocaine following 
vehicle pretreatment nor saline injection following normetanephrine pretreatment reinstated preference. However, injection 
of 0.093 mg/kg cocaine did reinstate preference when it was administered following normetanephrine pretreatment 
(*P<0.05 vs Normet/0 mg/kg cocaine and Veh/0.093 mg/kg cocaine; Figure 4a). No significant effects cocaine or 
normetanephrine pretreatment were observed in OCT3 KO mice (Figure 4b). 
DISCUSSION 
We previously reported that, under conditions in which stressors do not directly evoke cocaine seeking 
in rats, they can ‘set the stage’ for relapse, enhancing the reinstatement of cocaine seeking in response to 
an otherwise subthreshold priming dose of cocaine (Graf et al, 2013; McReynolds et al, 2016). These 
stage-setting effects of stress are mediated by glucocorticoids (Graf et al, 2013). The ability of electric 
footshock stress to potentiate reinstatement is eliminated by surgical adrenalectomy and is reproduced in 
the absence of shock by administration of corticosterone at a dose that reproduces plasma levels 
observed during stress. Here we demonstrate that stress-level corticosterone administration also 
potentiates cocaine-induced reinstatement of extinguished CPP in mice. Following CPP, cocaine dose-
dependently reinstated preference for the cocaine-paired compartment. As reported in rats, pretreatment 
of mice with corticosterone, at a dose that alone did not produce reinstatement, increased the sensitivity 
to cocaine-induced reinstatement as indicated by a leftward shift in the cocaine dose–response curve. 
The ability of circulating glucocorticoids to influence relapse susceptibility is significant in that elevated 
cortisol levels in cocaine-dependent human subjects are associated with stress- and cue-induced 
increases in subjective craving measures (Sinha et al, 1999) and that craving measures can be predicted 
by individual cortisol responses (Sinha et al, 2006). Thus identifying mechanisms through which 
glucocorticoids promote cocaine seeking may guide the development of interventions aimed at relapse 
prevention. 
The establishment of a protocol for assessing corticosterone-potentiated cocaine seeking in mice is 
significant, as it permits the utilization of available transgenic mouse models to study the glucocorticoid-
dependent mechanisms through which stressors promote cocaine use. One mechanism of interest is the 
OCT (OCT3), a low-affinity, high-capacity monoamine transporter that is inhibited by glucocorticoids. 
Using our rat model, we previously provided indirect evidence that glucocorticoid treatment potentiates 
subthreshold cocaine-induced reinstatement by inhibiting OCT3-mediated dopamine clearance in the 
NAc (Graf et al, 2013). Specifically, we found that the effect of corticosterone on cocaine-primed 
reinstatement (1) was not blocked by the GR antagonist RU486, (2) was reproduced by intra-NAc 
corticosterone injections, (3) was dependent on NAc dopamine receptor activation and (4) was 
associated with potentiation of the NAc dopamine response to cocaine. Importantly, we demonstrated 
that acute treatment of rats with stress-level corticosterone decreased dopamine clearance via a DAT-
independent mechanism and that stress- and corticosterone-induced potentiation of cocaine-primed 
reinstatement were reproduced by administration of the non-glucocorticoid OCT3 blocker, 
normetanephrine. In the present study, we demonstrate that pretreatment with either corticosterone or 
normetanephrine potentiates low-dose cocaine-induced reinstatement of extinguished CPP in mice. As 
with corticosterone, normetanephrine, at a dose that fails to re-establish preference for the cocaine-
paired compartment, produces a leftward shift in the dose–response curve for cocaine-primed 
reinstatement. 
Although collectively these findings strongly suggest that corticosterone enhances cocaine seeking by 
inhibiting OCT3-mediated transport, they are not conclusive. To more rigorously test the hypothesis that 
corticosterone acts by blocking OCT3, we examined the effects of OCT3 inhibitors on low-dose 
cocaine-induced reinstatement in wild-type and OCT3-deficient mice (Zwart et al, 2001). Prior work 
using these mice has implicated OCT3 in anxiety-related behavioral responses (Vialou et al, 2008) and 
in salt appetite (Vialou et al, 2004). However, there are, to our knowledge, no reports on the effects of 
corticosterone on behavior in OCT3-deficient mice. Here, in the first studies to examine the role of this 
corticosterone-sensitive transporter in behavioral actions of the hormone, we demonstrate that the ability 
of corticosterone to potentiate cocaine-primed reinstatement is eliminated in OCT3-deficient mice. 
Pretreatment with corticosterone potentiated low-dose cocaine-primed reinstatement of extinguished 
CPP in wild-type, but not in OCT3-deficient, mice. Thus these are the first studies to directly implicate 
OCT3, not only in corticosterone’s effects on cocaine seeking but also in any behavioral effect of 
corticosterone. 
OCT3-deficient mice did not display differences in the acquisition or extinction of cocaine-induced CPP 
and, despite hints of increased sensitivity to cocaine-primed reinstatement, did not display significant 
increases in CPP reinstatement in the absence of corticosterone or normetanephrine. This finding is 
somewhat surprising, given the well-established contribution of monoamines to the induction, retrieval, 
extinction, and reinstatement of cocaine-induced CPP. However, it is consistent with a previous study 
examining the effects of amphetamine and cocaine in OCT3-deficient mice. In that study, OCT3-
deficient mice displayed no differences in either amphetamine-induced CPP or behavioral sensitization 
to amphetamine compared with wild-type mice (Vialou et al, 2008). In the same study, OCT3-deficient 
mice did display enhanced locomotor responses to acute treatment with cocaine and amphetamine but 
only at very high doses of the drugs (Vialou et al, 2008). Whereas no differences in basal or low-to-
moderate dose (10 or 20 mg/kg, ip) cocaine-induced increases in locomotor activity were observed, the 
locomotor response to a very high cocaine dose (40 mg/kg, ip) was augmented in knockout mice. 
Definitive conclusions regarding the contribution of OCT3 to acquisition and reinstatement of CPP in 
the absence of corticosterone/normetanephrine will require testing across a broader range of cocaine 
doses during conditioning and reinstatement and is beyond the scope of the present study, which was 
aimed solely at confirming the contribution of OCT3 to the potentiating effects of corticosterone. 
Interestingly, although reductions in the total tissue content of dopamine and its metabolites have been 
found in OCT3 knockout mice (Vialou et al, 2008), basal extracellular dopamine, as measured using in 
vivo microdialysis, is not altered (Cui et al, 2009), suggesting that deletion of OCT3 may result in 
compensatory alterations in the expression of other transporters that limit effects on neurotransmission. 
Consistent with this possibility, it has been reported that constitutive deletion of one monoamine 
transporter often leads to changes in the expression and/or function of others (Shen et al, 2004; Baganz 
et al, 2008; Daws, 2009). Thus, while dopamine clearance at sites in which OCT3 represents the primary 
transport mechanism will be impaired in OCT3-deficient mice, increased expression of DAT and other 
dopamine-clearing transporters may compensate for the loss of OCT3-mediated dopamine clearance. 
For this reason, it is likely that the loss of OCT3-mediated clearance would be most evident under 
extreme conditions, when the capacity for other transporters to clear dopamine is limiting. This is 
consistent with a report that enhanced behavioral responses to cocaine and amphetamine were only 
observed in OCT3-deficient mice at very high doses of the drugs (Vialou et al, 2008). Under our 
hypothesis that the potentiating effects of corticosterone on reinstatement are attributable solely to its 
ability to inhibit OCT3, compensatory changes in the expression of other transporters would not be 
predicted to restore corticosterone sensitivity. 
The results of our previous studies in rats strongly suggest that corticosterone acts directly in the NAc to 
potentiate the effects of low-dose cocaine on behavior and dopamine signaling (Graf et al, 2013). 
Specifically: (a) direct delivery of corticosterone into this OCT3-expressing brain region potentiated 
low-dose cocaine effects on behavior (reinstatement); (b) the ability of ip corticosterone to potentiate 
reinstatement is blocked by intra-NAc injections of dopamine receptor antagonists; and (c) acute 
corticosterone treatment potentiates the effects of low-dose cocaine on extracellular dopamine 
concentrations measured using microdialysis and decreases DAT-independent dopamine clearance 
measured using fast-scan cyclic voltammetry. However, while these findings provide strong evidence 
for NAc dopamine in the effects of corticosterone, other sites of action and cellular mechanisms cannot 
be ruled out. OCT3 is expressed throughout the brain, including in other regions that contribute to 
cocaine-primed reinstatement, such as the prefrontal cortex (Gasser et al, 2009). Moreover, OCT3 
mediates corticosterone-sensitive transport of other monoamine substrates, including serotonin and 
norepinephrine (Gründemann et al, 1998a, 1998b). Both of these monoamines have also been implicated 
in the acute regulation of cocaine-seeking behavior (see, eg, Baker et al, 2001; Fletcher et al, 
2002; Burmeister et al, 2004; Nic Dhonnchadha et al, 2009) (Erb et al, 2000; Zhang and Kosten, 
2005; Platt et al, 2007; Mantsch et al, 2010). 
The present studies demonstrate that OCT3 expression is required for potentiation of low-dose cocaine-
induced reinstatement of cocaine seeking not only by corticosterone but also by the non-glucocorticoid 
OCT3 inhibitor normetanephrine. This is important, because, while normetanephrine is a potent 
inhibitor of OCT3-mediated transport (Martel et al, 1999), it has been reported to have other 
pharmacological effects, including weak agonist actions at alpha-1 adrenergic receptors (Langer and 
Rubio 1973) and low-affinity antagonism of alpha-2 adrenergic receptors (Lenz et al, 1991). The present 
findings indicate that, to the extent that these secondary pharmacological effects occur, the regulation of 
cocaine-induced reinstatement by normetanephrine is likely the result of OCT3 blockade, thereby 
validating the use of this compound as a pharmacological tool for studying OCT3-mediated processes. 
To summarize, using a CPP/reinstatement approach in mice, we provide converging lines of evidence 
that OCT3 is necessary for the potentiating effects of corticosterone on the reinstatement of cocaine-
seeking behavior. These results build on our prior findings in rats (Graf et al, 2013) to demonstrate, for 
the first time, that inhibition of OCT3 by corticosterone, likely via non-genomic effects on monoamine 
clearance, has behavioral consequences. Moreover, they pose OCT3 blockade as a potential mechanism 
through which stressful stimuli influence drug craving and relapse susceptibility and as a potential 
contributor to a wide range of stress-related behavioral responses. 
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